CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 24,407	$ 15,748
General and administrative	13,301	3,256
Total operating expenses	37,708	19,004
Loss from operations	37,708	19,004
Other (income) expense, net:
Change in fair value of anti-dilution right liability	0	682
Change in fair value of preferred stock tranche liability	0	9,928
Other (income)	(2,553)	(5)
Total other (income) expense, net	(2,553)	10,605
Net loss	$ 35,155	$ 29,609
Net loss per share of common stock, basic	$ 2.62	$ 7.32
Net loss per share of common stock, diluted	$ 2.62	$ 7.32
Weighted-average common stock outstanding, basic	13,426,066	4,043,416
Weighted-average common stock outstanding, diluted	13,426,066	4,043,416